Focus Financial Network Inc. lifted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 39.9% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 37,203 shares of the medical equipment provider’s stock after acquiring an additional 10,616 shares during the quarter. Focus Financial Network Inc.’s holdings in Boston Scientific were worth $1,588,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Renaissance Group LLC purchased a new stake in Boston Scientific in the fourth quarter worth about $28,064,000. PensionDanmark Pensionsforsikringsaktieselskab grew its holdings in shares of Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after acquiring an additional 28,961 shares during the period. Meiji Yasuda America Inc purchased a new position in shares of Boston Scientific during the 4th quarter worth approximately $4,708,000. Harvest Portfolios Group Inc. raised its position in shares of Boston Scientific by 6.1% in the 4th quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock worth $56,956,000 after acquiring an additional 34,598 shares in the last quarter. Finally, LBP AM SA raised its position in shares of Boston Scientific by 8.4% in the 4th quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock worth $41,419,000 after acquiring an additional 33,534 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Insider Activity
In other news, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 204,322 shares of company stock valued at $9,939,221. Company insiders own 0.34% of the company’s stock.
Boston Scientific Stock Performance
Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.
Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.
Analyst Ratings Changes
Several research firms recently weighed in on BSX. Argus restated a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Truist Financial dropped their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, TD Cowen reduced their target price on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.
Read Our Latest Research Report on BSX
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Read More
- Five stocks we like better than Boston Scientific
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
